Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis

Figures & data

Table 1. Demographics and baseline characteristics of the ITT population.

Characteristic	Tildrakizumab N = 55
Sex, n (%)
Female	27 (49.1)
Male	28 (50.9)
Age, years, mean (SD)	48.6 (15.3)
Race, n (%)
White	52 (94.5)
Black or African American	2 (3.6)
Asian	1 (1.8)
Ethnicity, n (%)
Hispanic or Latino	5 (9.1)
Not Hispanic or Latino	50 (90.9)
PGWBI score, mean (SD)	78.1 (14.1)
Anxiety	16.9 (4.0)
Depressed mood	12.5 (2.1)
Positive well-being	12.6 (3.3)
Self-control	12.9 (2.1)
General health	9.9 (2.5)
Vitality	13.3 (3.2)
DLQI score, mean (SD)	9.4 (5.2)
Itch-NRS, mean (SD)	6.6 (2.6)
Pain-NRS, mean (SD)	3.8 (3.2)
Scaling-NRS, mean (SD)	7.0 (2.3)

DLQI: Dermatology Life Quality Index; ITT: intention-to-treat; NRS: numerical rating scale; PGWBI: Psychological General Well-Being Index; SD: standard deviation.

Figure 1. Change from baseline in total PGWBI scores through Week 28 in patients treated with tildrakizumab. Data are shown as the mean for the intention-to-treat population; error bars represent the standard deviation. *p < .05; **p < .01. BL: baseline; PGWBI: Psychological General Well-Being Index; SD: standard deviation.

Figure 2. Change from baseline in PGWBI domain scores through Week 28 in patients treated with tildrakizumab. Results are shown for PGWBI domains (A) positive well-being, (B) general health, (C) anxiety, and (D) vitality. Data are presented as the mean for the intention-to-treat population; error bars represent the standard deviation. *p < .05; **p < .01; ***p < .001. BL: baseline; PGWBI: Psychological General Well-Being Index; SD: standard deviation.

Figure 3. Change from baseline in (A) PGWBI depressed mood and (B) self-control scores through Week 28 in patients treated with tildrakizumab. Data are shown as the mean for the intention-to-treat population for PGWBI domains (A) depressed mood and (B) self-control. Error bars represent the standard deviation. *p < .05. BL: baseline; PGWBI: Psychological General Well-Being Index; SD: standard deviation.

Figure 4. DLQI scores in patients treated with tildrakizumab. (A) Mean DLQI scores through Week 28 of treatment are presented. (B) Proportions of patients (n/N [%]) with a DLQI score of 0/1, a DLQI score of ≤5, or a ≥5-point reduction in DLQI score from baseline at Week 28 are shown. Panel A, *p < .001. Data are from the intention-to-treat population. Per (A), statistical significance was calculated per change from baseline. BL: baseline; DLQI: Dermatology Life Quality Index; SD: standard deviation.

Figure 5. NRS scores in patients treated with tildrakizumab. Mean ± SD (A) Itch-NRS, (B) Pain-NRS, and (C) Scaling-NRS scores through Week 28. Data are from the intention-to-treat population. Missing data were not imputed; error bars represent the SD. *p < .05, **p < .001. Statistically significant change from baseline based on Student’s t-test. BL: baseline; NRS: Numerical Rating Scale; SD: standard deviation.

Data availability statement

Data and other documents will be made available after publication, with no end date, to anyone who submits a reasonable request to the study sponsor.